Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can reach Katie on Signal at palmer.01.

In biology circles, Google’s AI research company DeepMind is best known for folding proteins. Its deep learning model AlphaFold, which predicts the structure of a protein from its sequence of amino acids, shared the Nobel Prize in chemistry last year with the University of Washington’s David Baker. 

But DeepMind has lately been working on a much gnarlier precursor problem: predicting how DNA encodes gene regulation. In a preprint and blog post published on Wednesday, it announced its latest stab at the challenge with a new model called AlphaGenome, an early step toward possible applications in therapeutic development. 

Compared with the well-defined problem of protein structure prediction, “genomics is more of a fuzzy field,” said DeepMind research engineer Natasha Latysheva. “There’s no single metric of success.” So DeepMind has gone after as many of them as it can.

STAT+ Exclusive Story

STAT+



This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe